Japan's Central Social Insurance Medical Council (Chuikyo) has started discussions on a re-calculation method for pharmaceutical products in relation to market expansion, as part of the National Health Insurance drug pricing reform for the fiscal year 2010 through its Expert Committee on the NHI Drug pricing.
The issue has been the subject of considerable debate between the government, the pharmaceutical industry and the various health care payer organizations, which have expressed strongly disparate views on the calculation system (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze